People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CiVi Biopharma Holdings, Inc. | — | Biotechnology | Series C | $76.5M | $972.2M | 2018 |
| Clene Nanomedicine, Inc. | — | Pharmaceuticals | Series C | $48.7M | $1.4B | 2020 |
| Clene Inc. | — | Pharmaceuticals | Series A | $16.6M | $33.6M | 2021 |
Shalom Jacobovitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shalom Jacobovitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Stevens | 2 | 6 |
| Reed Wilcox | 2 | 2 |
| Alison Mosca | 2 | 2 |
| David Matlin | 1 | 4 |
| Chidozie Ugwumba | 1 | 3 |
| Aaron Davis | 1 | 3 |
| Matthew Pietras | 1 | 2 |
| Carole Nuechterlein | 1 | 2 |
| Mark Mortenson | 1 | 2 |
| Jonathon Gay | 1 | 2 |
| Ryan Lund | 1 | 2 |
| Arjun Dee Desai | 1 | 1 |
| Robert Glanzman | 1 | 1 |
| Tae Heum Jeong | 1 | 1 |
| Fiona Costello | 1 | 1 |
| Robert Etherington | 1 | 1 |
| Christopher Fuglesang | 1 | 1 |
| Henrik Oerum | 1 | 1 |
| Chad Young | 1 | 1 |
| David Lisonbee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.